يوليو شنومكس: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
تقوم ACT Therapeutics و GenScript ProBio بتوقيع عقد لتطوير وإنتاج نواقل البلازميد والفيروسات لأول خط أنابيب لمنصة CAR-T المتقدمة لـ ACT Therapeutics (منصة ACT) ، والتي سيتم تكليفها أيضًا بإنتاج المواد الخام لخطوط الأنابيب اللاحقة ACT Therapeutics. سيغطي العقد إنتاج البلازميدات وناقلات الفيروسات لأول خط أنابيب لمنصة CAR-T المتقدمة لـ ACT Therapeutics.
نتيجة لهذه الاتفاقية ، تم ترقية GenScript ProBio إلى مرتبة الشريك العالمي القادر على دعم منصات ACT الخاصة بعلاجات ACT.
منصة ACT عبارة عن تقنية علاج جيني وخلايا من الجيل التالي تستهدف مستضدات السرطان عن طريق إدخال جينات مصممة لاستهداف هذه المستضدات في الخلايا المناعية. يتم تسليم هذه الجينات إلى الخلايا المناعية من خلال استخدام ناقلات الفيروس. تمتلك GenScript ProBio عملية تطوير عالية الجودة لناقلات الفيروسات ومنصة خدمة شاملة لإنتاج GMP ، وكلاهما ضروري لتطوير العلاج بالخلايا والجينات.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing سرطان الدم. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
قال Seogkyoung-Kong ، الرئيس التنفيذي لشركة ACT Therapeutics ، "لقد أكملنا الاستعدادات لمنصة ACT للظهور عالميًا من خلال شراكة إستراتيجية مع GenScript ProBio. سوف نسرع في تطوير العلاجات التي تستهدف السرطانات الصلبة المقاومة للحرارة والمستعصية ".
حول GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
لتحقيق مهمة "الابتكار من خلال التعاون" ، تلتزم GenScript ProBio بمساعدة العملاء على تقصير الجدول الزمني لتطوير الأدوية البيولوجية من الاكتشاف إلى التسويق ، وخفض تكاليف البحث والتطوير بشكل كبير وبناء مستقبل أكثر صحة.
